在人工智能（Artificial Intelligence, ...

Over half of CEOs globally are experimenting with AI to generate text, images and other forms of data, a recent joint survey by Fortune and Deloitte found. Meanwhile, a third of organizations are ...

Technically, Mark Sleeper doesn't know for sure he didn't get the placebo, but nothing in his 27 years of fighting the deadly lung disease cystic fibrosis has made him feel as good as the pill he ...

Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...

Vertex 股票已触及新的52周低点18.54美元，标志着该公司的重大下滑。根据 InvestingPro 数据，过去一年Vertex经历了急剧下跌，股价暴跌66.67%。仅在过去六个月内，该股已下跌45.5%，目前交易价格比其52周高点60.71美元低69%。这一下跌反映了持续的挑战和市场压力，这些因素严重影响了公司的表现，该公司在过去十二个月内未能实现盈利。当前的价格水平凸显了投资者的担忧， ...

Roughly a year ago, Google announced the launch of Vertex AI, a managed AI platform designed to help companies to accelerate the deployment of AI models. To mark the service’s anniversary and the ...

Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue growth.

Vertex brought in more than $9.8 billion last year thanks to its flagship cystic fibrosis drugs. The company is moving closer to the finish line with a new cystic fibrosis treatment that may even beat ...

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain ...

The heritage British brand has been revived by a chairman whose impressive career before watchmaking includes a three-year stint with Elon Musk. You can find the Vertex Watch Company tucked among the ...